Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Brexpiprazole
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brexpiprazole (Rexulti) is an adjunctive therapy to antidepressants in adults with major depressive disorder and as a treatment for schizophrenia in adults and children ages 13 years and older.
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2022
Lead Product(s) : Brexpiprazole
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable